|
|
ricerca
nel sito motori di rierca
|
|
|
|
|
documenti nella sezione
|
|
|
analisi della letteratura
in merito alla comunicazione facilitata
(cenciarelli i., mona a., 1999)
autismo:
è legato alla carenza di un enzima? - abstract
(cohen e., 1997)
autismo e linguaggio
(atzori g., 2003)
autismo ed epilessia
(a cura del prof. curatolo p., 1999)
dimetilglicina, un
metabolite non tossico e l'autismo
(rimland b., 1996)
i testi dei facilitati
svolgono le funzioni della lingua parlata?
(cenciarelli i., 1999)
il legame fra il
vaccino mmr e l'autismo ora è più chiaro
(fracer l., 2000)
il profilo cognitivo
delle persone autistiche
(mona a., 1999)
l'autismo: nuovi
esami per trovarne le cause e migliorarne la prognosi
(hanau c., tratto dal sito 'autismo triveneto', 1999)
l'intervento evolutivo
multicomponenziale (i.e.m.) in soggetti autistici
(guazzo g. m., aliperta d., cozzolino g., fabrizio c., liotta
d., trinchese i., pervenuto alla bma il 12-11-2000)
l'uso di diete senza
glutine e caseina con persone con autismo
(autism research unit, 1999)
la comunicazione
facilitata in ambito giudiziario
(cenciarelli i., mona a., 1999)
le rappresentazioni
della relazione tra operatori e bambini autistici
(d'amore s., onnis l., 1998)
linguaggio segnato
o comunicazione simultanea
(edelson s. m.)
risultati a lungo
termine per bambini con autismo che hanno ricevuto un trattamento
comportamentale intensivo precoce
(O. I. Lovaas, J. J. McEachin, T. Smith, 1993)
ruolo dell'immunogenetica
nella diagnosi di patologie post-vaccinali nel sistema nervoso centrale
- abstract
(montinari m. g., 1995)
secretina, aggiornamento
di dicembre 1999: la questione della sicurezza
(rimland b., 1999)
secretina: notizie
positive e negative alla "fine del primo inning"
(rimland b., 1999)
sistema immunitario
e autismo: alcune considerazioni
(colamaria v., pervenuto alla bma il 18-04-2001)
teoria della mente
e autismo
(atzori g., 2003)
trattamento comportamentale
ed educazione normale e funzionamento intellettivo nei bambini
autistici
(lovaas o. i., 1987)
un trattamento
omeopatico per l'autismo
(micozzi a., benassi f., 2002)
|
|
|
indietro
| inizio
|
|
|
THE USE OF GLUTEN AND CASEIN FREE DIETS WITH PEOPLE WITH AUTISM
The Autism Research Unit, 1999 (direttore Paul Shattock)
Autism
Research Unit, 41182 Adams Avenue,
San Diego, CA 92116.
(testo in italiano)
These notes should be taken as observations. They do not constitute
a recommendation or endorsement of a dietary method to alleviate
the symptoms of autism. Any decision to undertake such a method
must lie solely with the person with autism or with those having
responsibility for their care. It is strongly recommended that anyone
considering such interventions seek the support of their medical
practitioner and, if possible, a knowledgeable dietician or nutritionist.
Background
In the early 1980s a number of researchers, including Herman and
Panksepp, noted the similarities between the behavioural effects
on animals of opioids, such as morphine, and the symptoms of autism.
In a very speculative paper, Panksepp proposed a mechani sm whereby
people with autism may have elevated levels of opioids which occur
naturally in the CNS (=brain) of humans. The best known of these
naturally occurring opioid compounds is beta-endorphin (=endogenous
morphine) and certainly there is a degree of correlation between
the known effects of this compound and the symptoms of autism. Just
after this, Gillberg produced evidence of elevated levels of "endorphin
like substances" in the cerebro-spinal fluid of some people
with autism. In particular, elevat ed levels appeared in those children
who appeared to feel pain less than the normal population and who
exhibited self-injurious behaviour. At about the same time, Reichelt
produced evidence of abnormal peptides in the urine of people with
autism. We ourse lves, like a number of other groups, attempted
to replicate his findings. Although his method was comparatively
simple there were technical difficulties and these attempts were,
initially unsuccessful. Later on we switched to a more sophisticated
techniqu e and have been able to confirm Reichelt's findings. In
the urine of about 70-80% of people with autism there appear to
be elevated levels of substances with physico/chemical properties
similar to those expected from opioid peptides.The quantities of
thes e compounds, as found in the urine, are much too large to be
of CNS origin. The quantities are such that they can only have been
derived from the incomplete breakdown of certain foods. Proteins
consist of long chains of units known as amino-acids. Normall y
proteins are digested by enzymes in the intestines being broken
down into these units. However, if for some reason, this digestion
is incomplete, short chains of these amino-acids (known as peptides)
will result. It is proposed that these peptides may b e biologically
active and could result in the symptoms which we see in autism.
The majority of these peptides will be dumped in the urine, which
is where Reichelt and we are finding them. A small proportion will
cross into the brain and interfere with tra nsmission in such a
away that normal activity is altered or disrupted. It may be that
these compounds, themselves, have a direct effect upon transmission
or that they will attach themselves to the enzymes which would break
down our own naturally occurring enzymes. The consequences would
be the same in either case.It is well known that casein (from human
or cow milk) will break down in the stomach to produce a peptide
known as casomorphine which, as the name implies, will have opioid
activities. Similar ef fects are noted with gluten from wheat and
some other cereals in which case the compounds formed are gluteomorphins.If
this opioid excess hypothesis is correct, there are a number of
strategies which can be adopted. Firstly the anti-opioid drug "naltrexon
e" could be considered and promising results have been reported.
Not all of the reported trials on Naltrexone have produced positive
benefits but where appropriate, very low dose, therapies are employed,
the results seem to be better. Alternatively, a die t which excludes
casein (milk and dairy produce) or gluten (wheat and some other
cereal products) could be considered. It may be possible to determine,
from the pattern of the urinary peptides whether casein or wheat
or both should be avoided but such con clusions may be premature
at this stage. It has been observed that those children whose autism
appears at or around the time of birth may have a problem with casein
whereas those whose autism becomes apparent at about two years of
age, when a wheat based diet is more likely to be adopted, have
particular difficulties with gluten. Some children may have difficulty
with both.Norwegian colleagues of Reichelt have published data which
support the effectiveness of such dietary programmes but these studies
cann ot be considered as conclusive. There have been no other real
attempts to demonstrate the effectiveness of such diets on a scientific
basis. Numerous people have experimented on an individual basis
and have reported successful responses but such evidence cannot
be considered as, in any way, conclusive. In RimlandÆs studies of
parental reports, however, the results appear to be very much superior
to those obtained with any drug based therapy.
Practical Aspects
The theoretical processes described here are toxicological in nature
rather than allergic. The results are akin to poisoning rather than
an extreme sensitivity such as occurs in coeliac disease or sensitivity
to certain food colourings. Removal of gluten and/or casein containing
products requires the active participation of all those concerned
with the child's well-being. Tests have often been ruined by a well
meaning relative who ignores parental instruction or by schools
or therapists who feel that the proposals are rubbish. Carers must
satisfy themselves that the diet is being adhered to before any
evaluation is possible. Gluten and Casein free products, together
with advice on their use, are available from Pharmacies. Nutritionist
and dieticians woul d also be able to advise. Initially the reported
effects may be negative. Upset stomach, anxiety, clinginess, dizziness,
aches and pains and slight ill-temper have all been reported. Experience
would suggest that these are good signs and precursors of a p ositive
response. Reichelt recommends a trial period of three months. If
it has not worked within that time it is unlikely to do so. Experience
also suggests that the results are more easily demonstrated in younger
children. The effects in fully grown ind ividuals appear less impressive.
It should also be noted that the withdrawal effects may also be
more noticeable in small children and that these can sometimes be
very marked. Where younger children are involved (less than 4 years
old for example), it may be appropriate to withdraw the offending
foods in stages over a period of two weeks. Given that there appear
to be a number of possible causes of autism it is not unexpected
that no unitary solution will be found for all cases.
Conclusions
Although the hypotheses may appear "off the wall" in
many respects, there are a number of pieces of evidence which support
them. The ideas are compatible with virtually all the accepted biological
data on autism and are worthy of consideration.The dietary method
must still be considered as experimental and no positive results
can be promised or are claimed. The use of diet may well be far
less harmful than other medical interventions or therapeutic regimes
but care is still necessary during its implementa tion. We would
be pleased to receive any feedback of a positive or negative nature
from anyone utilising such dietary modification in the amelioration
of autism.
|